> top > projects > Inflammaging > docs > PubMed:26494468 > annotations
Inflammaging  

PubMed:26494468 JSONTXT 36 Projects

Annnotations TAB TSV DIC JSON TextAE-old TextAE

Id Subject Object Predicate Lexical cue
T1 0-132 Sentence denotes DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53.
T1 0-132 Sentence denotes DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53.
T2 133-246 Sentence denotes Mutation in the TP53 gene positively correlates with increased incidence of chemoresistance in different cancers.
T2 133-246 Sentence denotes Mutation in the TP53 gene positively correlates with increased incidence of chemoresistance in different cancers.
T3 247-452 Sentence denotes In this study, we investigated the mechanism of chemoresistance and epithelial-to-mesenchymal transition (EMT) in colorectal cancer involving the gain-of-function (GOF) mutant p53/ephrin-B2 signaling axis.
T3 247-452 Sentence denotes In this study, we investigated the mechanism of chemoresistance and epithelial-to-mesenchymal transition (EMT) in colorectal cancer involving the gain-of-function (GOF) mutant p53/ephrin-B2 signaling axis.
T4 453-620 Sentence denotes Bioinformatic analysis of the NCI-60 data set and subsequent hub prediction identified EFNB2 as a possible GOF mutant p53 target gene, responsible for chemoresistance.
T4 453-620 Sentence denotes Bioinformatic analysis of the NCI-60 data set and subsequent hub prediction identified EFNB2 as a possible GOF mutant p53 target gene, responsible for chemoresistance.
T5 621-735 Sentence denotes We show that the mutant p53-NF-Y complex transcriptionally upregulates EFNB2 expression in response to DNA damage.
T5 621-735 Sentence denotes We show that the mutant p53-NF-Y complex transcriptionally upregulates EFNB2 expression in response to DNA damage.
T6 736-900 Sentence denotes Moreover, the acetylated form of mutant p53 protein is recruited on the EFNB2 promoter and positively regulates its expression in conjunction with coactivator p300.
T6 736-900 Sentence denotes Moreover, the acetylated form of mutant p53 protein is recruited on the EFNB2 promoter and positively regulates its expression in conjunction with coactivator p300.
T7 901-1030 Sentence denotes In vitro cell line and in vivo nude mice data show that EFNB2 silencing restores chemosensitivity in mutant p53-harboring tumors.
T7 901-1030 Sentence denotes In vitro cell line and in vivo nude mice data show that EFNB2 silencing restores chemosensitivity in mutant p53-harboring tumors.
T8 1031-1207 Sentence denotes In addition, we observed high expression of EFNB2 in patients having neoadjuvant non-responder colorectal carcinoma compared with those having responder version of the disease.
T8 1031-1207 Sentence denotes In addition, we observed high expression of EFNB2 in patients having neoadjuvant non-responder colorectal carcinoma compared with those having responder version of the disease.
T9 1208-1414 Sentence denotes In the course of deciphering the drug resistance mechanism, we also show that ephrin-B2 reverse signaling induces ABCG2 expression after drug treatment that involves JNK-c-Jun signaling in mutant p53 cells.
T9 1208-1414 Sentence denotes In the course of deciphering the drug resistance mechanism, we also show that ephrin-B2 reverse signaling induces ABCG2 expression after drug treatment that involves JNK-c-Jun signaling in mutant p53 cells.
T10 1415-1567 Sentence denotes Moreover, 5-fluorouracil-induced ephrin-B2 reverse signaling promotes tumorigenesis through the Src-ERK pathway, and drives EMT via the Src-FAK pathway.
T10 1415-1567 Sentence denotes Moreover, 5-fluorouracil-induced ephrin-B2 reverse signaling promotes tumorigenesis through the Src-ERK pathway, and drives EMT via the Src-FAK pathway.
T11 1568-1826 Sentence denotes We thus conclude that targeting ephrin-B2 might enhance the therapeutic potential of DNA-damaging chemotherapeutic agents in mutant p53-bearing human tumors.Cell Death and Differentiation advance online publication, 23 October 2015; doi:10.1038/cdd.2015.133.
T11 1568-1826 Sentence denotes We thus conclude that targeting ephrin-B2 might enhance the therapeutic potential of DNA-damaging chemotherapeutic agents in mutant p53-bearing human tumors.Cell Death and Differentiation advance online publication, 23 October 2015; doi:10.1038/cdd.2015.133.